MX2018009955A - Anticuerpo anti-cd20 quimerico canino. - Google Patents
Anticuerpo anti-cd20 quimerico canino.Info
- Publication number
- MX2018009955A MX2018009955A MX2018009955A MX2018009955A MX2018009955A MX 2018009955 A MX2018009955 A MX 2018009955A MX 2018009955 A MX2018009955 A MX 2018009955A MX 2018009955 A MX2018009955 A MX 2018009955A MX 2018009955 A MX2018009955 A MX 2018009955A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- canine anti
- chimeric canine
- chimeric
- hodgkins
- Prior art date
Links
- 241000282465 Canis Species 0.000 title abstract 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a anticuerpos anti-CD20 quiméricos caninizados para la proteína canina CD20 y a métodos de uso para tratar ciertos trastornos tales como el linfoma de células B no Hodgkins en perros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296729P | 2016-02-18 | 2016-02-18 | |
| PCT/US2017/017337 WO2017142800A1 (en) | 2016-02-18 | 2017-02-10 | Chimeric canine anti-cd20 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009955A true MX2018009955A (es) | 2018-11-29 |
Family
ID=58098709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009955A MX2018009955A (es) | 2016-02-18 | 2017-02-10 | Anticuerpo anti-cd20 quimerico canino. |
| MX2022014375A MX2022014375A (es) | 2016-02-18 | 2018-08-16 | Anticuerpo anti-cd20 quimerico canino. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014375A MX2022014375A (es) | 2016-02-18 | 2018-08-16 | Anticuerpo anti-cd20 quimerico canino. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10519244B2 (es) |
| EP (1) | EP3416984B1 (es) |
| JP (1) | JP6661019B2 (es) |
| KR (1) | KR102131544B1 (es) |
| CN (1) | CN108699152B (es) |
| AU (1) | AU2017219596B2 (es) |
| BR (1) | BR112018016367A2 (es) |
| CA (1) | CA3014461C (es) |
| DK (1) | DK3416984T3 (es) |
| EA (1) | EA039434B1 (es) |
| ES (1) | ES2868650T3 (es) |
| MX (2) | MX2018009955A (es) |
| NZ (1) | NZ744192A (es) |
| WO (1) | WO2017142800A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA039434B1 (ru) * | 2016-02-18 | 2022-01-27 | Эланко Юэс Инк. | Химерное собачье анти-cd20 антитело |
| EP3668536A4 (en) | 2017-08-15 | 2021-05-26 | Kindred Biosciences, Inc. | IGG-FC VARIANTS FOR USE IN VETERINARY MEDICINE |
| JP2021059499A (ja) | 2019-10-03 | 2021-04-15 | 日本全薬工業株式会社 | イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント |
| KR20240021959A (ko) * | 2021-06-17 | 2024-02-19 | 펫메딕스 리미티드 | 항개 cd20 항체 |
| WO2023010057A1 (en) * | 2021-07-28 | 2023-02-02 | Atreca, Inc. | Atrc-101 target expression assay |
| GB202217993D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
| AU2023417626A1 (en) | 2022-12-27 | 2025-07-10 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2024155982A2 (en) | 2023-01-20 | 2024-07-25 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| WO2025121944A1 (ko) * | 2023-12-08 | 2025-06-12 | 주식회사 박셀바이오 | 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1519959B1 (en) * | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| JP4745242B2 (ja) * | 2003-05-20 | 2011-08-10 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｃｄ２０結合分子 |
| WO2009086072A2 (en) * | 2007-12-21 | 2009-07-09 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
| EP2411050A4 (en) * | 2009-03-25 | 2013-07-17 | Vet Therapeutics Inc | ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE |
| EP2496604B1 (en) * | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| AU2011221553B2 (en) | 2010-03-04 | 2016-05-26 | Vet Therapeutics Inc. | Monoclonal antibodies directed to CD20 |
| GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| WO2013054127A1 (en) * | 2011-10-13 | 2013-04-18 | Nvip Pty Ltd | Canine/feline cd20 binding epitope and compositions for binding thereto |
| WO2013063186A2 (en) * | 2011-10-26 | 2013-05-02 | Novartis Animal Health Us, Inc. | Monoclonal antibodies and methods of use |
| ES2743809T3 (es) * | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| EA039434B1 (ru) * | 2016-02-18 | 2022-01-27 | Эланко Юэс Инк. | Химерное собачье анти-cd20 антитело |
-
2017
- 2017-02-10 EA EA201891499A patent/EA039434B1/ru unknown
- 2017-02-10 DK DK17706644.6T patent/DK3416984T3/da active
- 2017-02-10 KR KR1020187023393A patent/KR102131544B1/ko active Active
- 2017-02-10 JP JP2018539354A patent/JP6661019B2/ja active Active
- 2017-02-10 EP EP17706644.6A patent/EP3416984B1/en active Active
- 2017-02-10 CN CN201780011511.5A patent/CN108699152B/zh active Active
- 2017-02-10 BR BR112018016367A patent/BR112018016367A2/pt not_active Application Discontinuation
- 2017-02-10 AU AU2017219596A patent/AU2017219596B2/en active Active
- 2017-02-10 CA CA3014461A patent/CA3014461C/en active Active
- 2017-02-10 NZ NZ74419217A patent/NZ744192A/en unknown
- 2017-02-10 US US16/073,927 patent/US10519244B2/en active Active
- 2017-02-10 MX MX2018009955A patent/MX2018009955A/es unknown
- 2017-02-10 ES ES17706644T patent/ES2868650T3/es active Active
- 2017-02-10 WO PCT/US2017/017337 patent/WO2017142800A1/en not_active Ceased
-
2018
- 2018-08-16 MX MX2022014375A patent/MX2022014375A/es unknown
-
2019
- 2019-11-14 US US16/683,518 patent/US10941206B2/en active Active
-
2021
- 2021-02-04 US US17/167,685 patent/US20210163618A1/en not_active Abandoned
-
2023
- 2023-04-20 US US18/303,769 patent/US12195548B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10941206B2 (en) | 2021-03-09 |
| NZ744192A (en) | 2019-11-29 |
| JP6661019B2 (ja) | 2020-03-11 |
| CN108699152B (zh) | 2022-08-19 |
| CA3014461A1 (en) | 2017-08-24 |
| EA201891499A1 (ru) | 2019-01-31 |
| US20190194342A1 (en) | 2019-06-27 |
| US20200131273A1 (en) | 2020-04-30 |
| CN108699152A (zh) | 2018-10-23 |
| ES2868650T3 (es) | 2021-10-21 |
| EP3416984A1 (en) | 2018-12-26 |
| KR102131544B1 (ko) | 2020-07-07 |
| WO2017142800A1 (en) | 2017-08-24 |
| JP2019507128A (ja) | 2019-03-14 |
| US20230257476A1 (en) | 2023-08-17 |
| AU2017219596B2 (en) | 2019-07-04 |
| AU2017219596A1 (en) | 2018-07-19 |
| CA3014461C (en) | 2023-02-28 |
| BR112018016367A2 (pt) | 2019-01-22 |
| US10519244B2 (en) | 2019-12-31 |
| MX2022014375A (es) | 2022-12-15 |
| US12195548B2 (en) | 2025-01-14 |
| EP3416984B1 (en) | 2021-03-31 |
| US20210163618A1 (en) | 2021-06-03 |
| DK3416984T3 (da) | 2021-04-26 |
| EA039434B1 (ru) | 2022-01-27 |
| KR20180096804A (ko) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014375A (es) | Anticuerpo anti-cd20 quimerico canino. | |
| PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| PH12017500825A1 (en) | Anti-cldn chimeric antigen receptors and methods of use | |
| NZ732568A (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| IL250831A0 (en) | Antibodies and chimeric antigen receptors specific for cd19, compositions containing same and uses thereof | |
| HK1252675A1 (zh) | 抗cd33抗体及其使用方法 | |
| EP4530630A3 (en) | Monoclonal antibodies and methods of use | |
| PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| PH12016501908A1 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| PH12018500710A1 (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
| MX379396B (es) | Conjugados de pirrolobenzodiazepina y anticuerpo. | |
| PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| AU2016245958A8 (en) | CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell | |
| MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
| MA40536A (fr) | Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations | |
| HK40006696A (en) | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma | |
| HK1243090A1 (en) | Anti-cldn chimeric antigen receptors and methods of use | |
| UA105682U (uk) | Препарат "кватронан-se" для стимуляції заплідненості корів |